BrightGene Bio-Medical Technology Co.,Ltd.

Borui biomedical technology (suzhou) co., LTD., founded in 2001 by Dr. Yuan jiandong, a returnee from the United States, is located in suzhou new drug innovation center in the high-tech zone of suzhou, a "high-tech enterprise in jiangsu province" and supported by the innovation fund of the ministry of science and technology. Borui is committed to new drug development, production and sales of high-end API and intermediates. Since its establishment, the annual growth rate has exceeded 100%. Borui has extensive experience in new drug development, pharmaceutical engineering, biotechnology and pharmaceutical intellectual property markets. In the field of anti-virus, anti-tumor, cardiovascular and cerebrovascular have a strong technical reserve and technical innovation capacity. I have applied for 11 Chinese patents and one PCT world patent. Two new classes of drugs, bp-0018 and BP0083 (innovative hepatitis b drugs), have been transferred; The "entecavir synthetic process patent" technology authorized by a large domestic pharmaceutical enterprise has been approved by clinical approval. Breakthroughs have been made in the research of third-generation hepatitis b treatment drug BP0752 and chemotherapy drug BP07986 for liver cancer. Relying on technological innovation and research and development in key fields, borui continuously expands international customers, and provides customers with comprehensive services and better products. At present, over 90% of the raw drug and intermediate products of borui are sold abroad. Products like entecavir have a leading market share in Europe and America. In the future, borui will continue to adhere to the concept of innovation, take "innovation and improvement of health" as the target, commit to drug innovation, strive to expand the international market, and strive to become independent intellectual property as the core competitiveness in cancer